AZ Continues To Buy Pipeline With $100M Rigel Deal

Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet